Initiation of Parkinson's disease treatment.
Parkinson therapy should be commenced as soon as patients feel impaired by motor or other symptoms. Recently it has been stated, however, to start treatment immediately after the diagnosis of PD has been made, in order to offer some neuroprotection to active dopaminergic neurons and to prevent deleterious compensatory mechanisms in dopaminergic cells. The selection of the medication depends on the state of the disease, the clinical symptoms, concomitant diseases and age. In de novo patients, most guidelines, including those of the German Neurological Society, advocate to start with a dopamine agonist. In my opinion, initial treatment with a MAO-B-inhibitor and subsequent combination with a long-acting dopamine agonist may be even more promising with regard to neuroprotection, modification of the disease, avoidance of dyskinesia and good motor improvement.
Reichmann
Heinz
H
Klinik und Poliklinik für Neurologie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. Heinz.Reichmann@uniklinikum-dresden.de
D006801:Humans; D010300:Parkinson Disease / Q000628:therapy*; D013997:Time Factors
N Engl J Med. 2004 Dec 9;351(24):2498-508
15590952
Neurology. 1991 Feb;41(2 ( Pt 1)):202-5
1992362
N Engl J Med. 2000 May 18;342(20):1484-91
10816186
Mov Disord. 2005 Nov;20(11):1502-7
16037924
Neurology. 2007 Jan 23;68(4):272-6
17202432
Nat Rev Neurosci. 2006 Apr;7(4):295-309
16552415
Acta Neurol Scand. 1998 Mar;97(3):175-83
9531434
Ann Neurol. 2006 Mar;59(3):559-62
16489611
Arch Neurol. 2002 Dec;59(12):1937-43
12470183
Clin Ther. 2007 Dec;29(12):2654-66
18201581
Lancet Neurol. 2006 Aug;5(8):677-87
16857573
Exp Neurol. 2008 May;211(1):172-9
18321484